Skip to content

Safety and Efficacy of the mylife CamAPS FX system during resistance exercise in adults with type 1 diabetes - a randomized controlled crossover trial

Safety and Efficacy of the mylife CamAPS FX system during resistance exercise in adults with type 1 diabetes - a randomized controlled crossover trial - RExID

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00034995
Enrollment
25
Registered
2024-09-02
Start date
2024-08-31
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E10

Interventions

Group 1: Use of the automated mode of the pump (ease-off mode of the pump and setting the glucose target value to 120 mg/dL) Group 2: Use of the manual mode of the pump and reduction of the basal insu

Sponsors

Universität Bayreuth, Bayreuther Zentrum für Sportwissenschaft (BaySpo)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: - Informed consent obtained - Male or female aged 18–70 years (both inclusive) - Diagnosed with type 1 diabetes mellitus (>12 months) - HbA1c =10% (86 mmol/mol) - Use of the mylife CamAPS FX system or willing to be switched to the mylife CamAPS FX system over the duration of the study

Exclusion criteria

Exclusion criteria: - Recurrent severe hypoglycemia (severe hypoglycemia with loss of consciousness during the past 6 months) - Hypoglycaemia unawareness as assessed by Gold Score (=4) - Hospitalization for diabetic ketoacidosis during the previous 6 months - females who are pregnant as tested via pregnancy test

Design outcomes

Primary

MeasureTime frame
- t70-180: Time in range (%TiR; 70-180 mg/dL) during hypertrophy resistance training in comparison of trial arms (efficacy outcome) - tn<70: Total number of hypoglycemia (nTbR; <70 mg/dL for =5 min) during hypertrophy resistance training

Secondary

MeasureTime frame
-n180: Time above range 1 (%TaR1; >180 mg/dL), including readings of >250 mg/dL during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - t>250: Time above range 2 (%TaR2; >250 mg/dL) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - CV: Coefficient of variation (%) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - SD: Standard deviation of mean glucose during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - meanglu: mean sensor glucose (mg/dL) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - t70-140: Time in tight range (%TiTR; 70–140 mg/dL) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - eventrate>250: Extended hyperglycaemic event rate (nTaR; >250 mg/dL; for =5 min) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) (nTaR; >250 mg/dL; for =15 min) in comparison of trial arms - prop70-180: Proportion of participants with time in range (TiR; 70–180 mg/dL) for >70% during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - prop180: Proportion of participants with time above range 1 (TaR1; >180 mg/dL) for 270: Proportion of participants with time above range 2 (TaR2; 70% time in range 70–180 mg/dL and 70% time in range (TiR; 70–180 mg/dL) and <1% time below range 2 (TbR2; <54 mg/dL) during hypertrophy resistance training and during the 24h post-exercise period (day vs. nighttime) in comparison of trial arms - glunadir: Glucose nadir (mg/dL) during hypertrophy resistance training in comp

Countries

Germany

Contacts

Public ContactOthmar Moser

Universität Bayreuth, Bayreuther Zentrum für Sportwissenschaft (BaySpo)

othmar.moser@uni-bayreuth.de+49 (0)921 / 55-3465

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026